HopeStage
Back to all studies
CompletedNCT05145764

Sleep medication studied alongside buprenorphine for fentanyl use

About this titleRead the official source — NCT05145764
Medication studyAges 18–65United StatesAddiction
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
BaltimoreSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: March 30, 2022
Recruitment status
Completed
Enrollment listed in the registry
76
Sponsor
Johns Hopkins University
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT05145764
Official title
Show the full official title

Suvorexant as an Adjunct to Buprenorphine Induction and Maintenance in Persons Who Use Fentanyl

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Baltimore

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Johns Hopkins University, a university.

Did this study involve medication?

Yes. The study involved medication, including Suvorexant and Placebo.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies